Orient Bio Inc
KRX:002630
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1), the stock would be worth ₩580.55 (4% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | ₩556 |
0%
|
| 3-Year Average | 1 | ₩580.55 |
+4%
|
| 5-Year Average | 1.1 | ₩632.53 |
+14%
|
| Industry Average | 4.9 | ₩2 783.12 |
+401%
|
| Country Average | 1.1 | ₩640.67 |
+15%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Orient Bio Inc
KRX:002630
|
65.9B KRW | 1 | -8 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 132.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 2.4 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 3.8 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 3.8 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.7 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 11.5 | 45.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 4.2 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | -1 087.5 | 29.6 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2.3 |
| Max | 2 461.2 |
Other Multiples
Orient Bio Inc
Glance View
ORIENTBIO, Inc. engages in the research and development of biotechnology. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 104 full-time employees. The firm produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. The company also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.
